At NucleoTech, we’re focused on developing treatments for neurological disorders by solving the drug delivery problem, which remains the biggest challenge in treating most neurological diseases. Many promising drugs could be effective if they could reach the brain, but the blood-brain barrier prevents them from doing so. Developing a carrier that can safely shuttle drugs into the brain has the potential to turn many currently untreatable diseases into treatable ones.

We’ve successfully built a proprietary screening technology, which serves as the foundation for developing efficient carriers. We’re now screening hundreds of potential candidates, with the expectation that this will lead us to one that outperforms anything available today. Whereas many biotech companies may take a decade before they see revenue, we expect to begin licensing our carriers and generating revenue in 2027.